Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+50 21-DAY vs ESTROSTEP FE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.
Prevention of pregnancy
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no known contraindications, who have achieved menarche)
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours. Clinical context: Steady-state reached within 7-10 days.
Mestranol is demethylated to ethinyl estradiol; ethinyl estradiol and norethindrone are metabolized by CYP3A4. Conjugation (glucuronidation and sulfation) occurs in the liver and gut wall.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone acetate: hydrolyzed to norethindrone, then metabolized by reduction and glucuronidation.
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Renal: ~40% as metabolites; fecal: ~30% (biliary); remainder as conjugates.
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: ~97% bound to albumin, 2-3% free
Ethinyl estradiol: 97-98% bound to albumin and SHBG; norethindrone acetate: 91-95% bound to albumin and SHBG.
Norethindrone: Vd approximately 4 L/kg; Ethinyl estradiol: Vd approximately 2.5 L/kg; indicates extensive tissue distribution
Ethinyl estradiol: 2.3-3.6 L/kg; norethindrone acetate: 1.5-2.5 L/kg. Indicates extensive tissue distribution.
Oral: Norethindrone ~90%; Ethinyl estradiol ~97-98% (due to low first-pass metabolism)
Oral: Ethinyl estradiol ~45% (first-pass metabolism); norethindrone acetate ~64%.
No dosage adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid retention and hyperkalemia.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Use is contraindicated in patients with severely impaired renal function (GFR <30 m L/min/1.73 m²) due to potential for fluid retention and hyperkalemia.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh class C), or liver tumors. Dose adjustment not recommended for mild hepatic impairment (Child-Pugh A) but use with caution; avoid in moderate-to-severe impairment (Child-Pugh B or C).
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution and monitor liver function; no specific dose adjustment guidelines are established.
Not indicated in pediatric females before menarche. For postmenarchal adolescents, dose same as adults: one tablet orally once daily for 21 days.
Safety and efficacy have not been established in pediatric patients below 16 years of age. Post-pubertal adolescents may be dosed as adults, with careful consideration of risks (e.g., bone density).
Not indicated in postmenopausal women due to lack of efficacy and increased risk of thromboembolic events, cardiovascular disease, and malignancy.
Not indicated for use in women over 65 years due to lack of efficacy and safety data, and increased risk of cardiovascular and thrombotic events.
Cigarette smoking increases risk of serious cardiovascular side effects from combined oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women should not use combined oral contraceptives if they smoke and are over 35 years old.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and smoking intensity (especially >35 years). Women >35 years who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Carcinoma of reproductive organs (breast, endometrium),Hepatic adenoma or liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (optic neuritis, retinal thrombosis),Possible migraine exacerbation
Thromboembolic disorders, cardiovascular disease (MI, stroke), hypertension, gallbladder disease, hepatic neoplasia, lipid effects, glucose intolerance, headache, breakthrough bleeding, depression, contact lens intolerance, fluid retention, hereditary angioedema.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenoma or carcinoma, pregnancy, hypersensitivity to any component.
Grapefruit juice may inhibit CYP3A4 metabolism, increasing ethinyl estradiol levels and potential adverse effects (nausea, breast tenderness, thromboembolism). St. John's Wort may decrease contraceptive efficacy. No significant interactions with other foods.
No specific food interactions are reported for Estrostep Fe. Grapefruit juice may slightly increase estrogen levels but is not considered clinically significant. There are no dietary restrictions. However, patients should maintain a consistent intake of folic acid if planning pregnancy; iron supplements can be taken with food to reduce GI upset.
FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trimesters: Associated with masculinization of female fetuses (pseudohermaphroditism) due to androgenic activity of norethindrone. Estrogen component may cause fetal harm. Discontinue immediately if pregnancy occurs.
Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects from sex hormones. Second/third trimester: feminization of male fetus, potential for urogenital malformations, and long-term reproductive tract effects. Postnatal: possible increased risk of childhood cancers.
Contraindicated in breastfeeding. Norethindrone and ethinyl estradiol are excreted in breast milk; M/P ratio for norethindrone is approximately 0.5. May reduce milk volume and quality. Known adverse effects include jaundice and breast enlargement in infants. Avoid use during lactation.
Excreted in breast milk in small amounts (estrogen M/P ratio ~0.2, progestin M/P ratio ~0.6). May reduce milk quantity and quality. Use caution; generally not recommended. No adverse effects reported in infants at typical doses.
Not applicable; use is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) could reduce efficacy of oral contraceptives, but no dose adjustments are warranted as the drug should not be used.
Contraindicated; no dose adjustment needed because drug should be discontinued immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) not applicable due to contraindication.
For combination oral contraceptives (COCs) like NORINYL 1+50, counsel patients that concurrent use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy. Advise backup contraception or alternate method. Norethindrone 1 mg/ethinyl estradiol 50 mcg has higher estrogen content; consider increased thromboembolism risk vs low-dose pills. Monitor for hypertension, migraine with aura, and breakthrough bleeding patterns.
Estrostep Fe is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol. It is unique among OCPs for its step-up estrogen regimen (20, 30, 35 mcg EE) intended to mimic natural menstrual cycle. Clinicians should note that it is not FDA-approved for acne treatment, though it is often used off-label; only Estrostep (non-Fe) is approved for acne. The iron (ferrous fumarate) in the last 7 tablets is a placebo. It is a low-dose pill; missed doses more likely cause breakthrough bleeding. Contraindications include smoking >35, history of DVT/PE, migraine with aura, liver disease, breast cancer. Counsel patients to take at same time daily; if missed, follow standard missed pill protocol.
Take one tablet daily at the same time, with or without food. Follow pack directions: 21 active pills then 7 placebo days.,Expect withdrawal bleeding during placebo week; if no bleed occurs, consider pregnancy test.,Missed pill: if delayed <12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days.,Common side effects: nausea, breast tenderness, headache; usually improve within 3 months.,Report severe leg pain/chest pain/sudden dyspnea/speech changes as possible signs of blood clot.,Avoid grapefruit juice as it may increase estrogen levels and side effects.,Does not protect against STIs; use condoms for prevention.
Take one pill at the same time each day. The first 21 pills contain active hormones; the last 7 pills are iron tablets (not hormones).,If you miss a pill, refer to the package insert or contact your healthcare provider. Use backup contraception (condoms) if pills are missed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Estrostep Fe does not protect against sexually transmitted infections (STIs). Always use condoms for STI prevention.,Smoking while using this pill increases risk of serious cardiovascular events. Do not smoke.,Contact your doctor if you experience signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron in the last 7 pills is to help with iron levels but does not provide hormonal contraception during that week.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+50 21-DAY vs ESTROSTEP FE, answered by our medical review team.
NORINYL 1+50 21-DAY is a Combined Oral Contraceptive that works by Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.. ESTROSTEP FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone acetate produces progestational effects including endometrial transformation and cervical mucus thickening, inhibiting sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+50 21-DAY and ESTROSTEP FE depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+50 21-DAY is: One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.. The standard adult dose of ESTROSTEP FE is: One tablet daily orally, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (24 active tablets) followed by ferrous fumarate 75 mg tablets (4 placebo tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+50 21-DAY and ESTROSTEP FE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+50 21-DAY is classified as Category C. FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trim. ESTROSTEP FE is classified as Category C. Category X. Estrostep FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is contraindicated in pregnancy. First trimester: increased risk of neural tube defects, cardiov. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.